In summary, in line with the clinical data, RBM3 expression is demonstrated to confer a more aggressive behavior by enhanced migration and invasion of pancreatic cancer cells, but also an increased sensitivity to chemotherapy in vitro. This evidence concerns the gene RBM3 and familial pancreatic carcinoma.